

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

1-24. (canceled)

25. (previously presented) An isolated cell comprising a nucleic acid encoding human amyloid precursor protein including the nucleotides encoding codon 670 and 671 of human amyloid precursor protein 770, or encoding the codons corresponding to these in other isoforms of APP, operably linked to a promoter, wherein the nucleic acid encodes an amino acid other than lysine at codon 670 and/or an amino acid other than methionine at codon 671 and, wherein the cell expresses a human amyloid precursor protein or fragment thereof which has an amino acid other than lysine at codon 670 and/or an amino acid other than methionine at codon 671.

26. (previously presented) The cell of claim 25, wherein the cell is immortalized.

27. (previously presented) An isolated cell comprising a nucleic acid encoding human amyloid precursor protein including the nucleotides encoding codon 670, 671 and 717 of human amyloid precursor protein 770, or encoding the codons corresponding to these in other isoforms of APP, operably linked to a promoter, wherein the nucleic acid encodes an amino acid other than lysine at codon 670 and/or an amino acid other than methionine at codon 671 and an amino acid other than valine at codon 717 and the cell expresses a human amyloid precursor protein or

fragment thereof which has an amino acid other than lysine at codon 670 and/or an amino acid other than methionine at codon 671 and an amino acid other than valine at codon 717.

28. (previously presented) The cell of claim 27, wherein the cell is immortalized.

29-30. (canceled)

31. (previously presented) A method of screening for an agent for treating Alzheimer's disease comprising contacting the cell of claim 25 with the agent and monitoring the expression or processing of amyloid precursor protein or fragments thereof.

32. (previously presented) A method of screening for an agent for treating Alzheimer's disease comprising contacting the cell of claim 27 with the agent and monitoring the expression or processing of amyloid precursor protein or fragments thereof.